Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Rash at injection site; severe aches; Fatigue; This non-serious case was reported by a nurse via sales rep and described the occurrence of injection site rash in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix (unknown arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site rash (Verbatim: Rash at injection site), pain (Verbatim: severe aches) and fatigue (Verbatim: Fatigue). The outcome of the injection site rash, pain and fatigue were resolved (duration 5 days). The reporter considered the injection site rash, pain and fatigue to be related to Shingrix. The company considered the injection site rash, pain and fatigue to be related to Shingrix. Additional Information: GSK Receipt Date:30-SEP-2025 The pediatric nurse practitioner was the patient who experienced the side effects herself. But it was not serious. No other products were received by the patient. The reporter stated she did not mind reporting the incident but did not want to be contacted for follow up. The batch number was not provided, and unable to contact the reporter.